MARKET

CMPS

CMPS

Compass Pathways Plc
NASDAQ
5.37
-0.27
-4.79%
After Hours: 5.54 +0.17 +3.17% 18:41 03/27 EDT
OPEN
5.61
PREV CLOSE
5.64
HIGH
5.70
LOW
5.31
VOLUME
1.68M
TURNOVER
--
52 WEEK HIGH
8.90
52 WEEK LOW
2.250
MARKET CAP
692.32M
P/E (TTM)
-1.7443
1D
5D
1M
3M
1Y
5Y
1D
Compass Pathways Price Target Cut to $18.00/Share From $20.00 by Canaccord Genuity
Dow Jones · 1d ago
Compass Pathways Is Maintained at Buy by Canaccord Genuity
Dow Jones · 1d ago
Canaccord Genuity Maintains Buy on Compass Pathways, Lowers Price Target to $18
Benzinga · 1d ago
Psychedelic: Compass Pathways, NRx Pharma report earnings results
TipRanks · 1d ago
RBC Capital Reaffirms Their Buy Rating on COMPASS Pathways (CMPS)
TipRanks · 2d ago
Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS) and Ionis Pharmaceuticals (IONS)
TipRanks · 2d ago
Compass Pathways price target lowered to $18 from $20 at Canaccord
TipRanks · 2d ago
Compass Pathways Is Maintained at Overweight by Morgan Stanley
Dow Jones · 2d ago
More
About CMPS
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.

Webull offers Compass Pathways PLC (ADR) stock information, including NASDAQ: CMPS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CMPS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CMPS stock methods without spending real money on the virtual paper trading platform.